A Comparison of Brand-Name Drug Prices Among Selected Federal Programs

Congressional Budget Office

No 56978, Reports from Congressional Budget Office

Abstract: The federal government is a major purchaser of prescription drugs, both directly through federal agencies, such as the Department of Defense, and indirectly through federal health insurance programs, such as Medicare Part D. In this report, CBO describes how the prices of brand-name prescription drugs are determined in different federal programs and compares drug prices among those programs in 2017.

JEL-codes: I10 I11 I13 I18 (search for similar items in EconPapers)
Date: 2021-02-18
New Economics Papers: this item is included in nep-ias and nep-ipr
References: Add references at CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
https://www.cbo.gov/system/files/2021-02/56978-Drug-Prices.pdf (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:cbo:report:56978

Access Statistics for this paper

More papers in Reports from Congressional Budget Office Contact information at EDIRC.
Bibliographic data for series maintained by ().